Amgen Inc. Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.6%projected annual EPS growth
Analyst Coverage
29analysts covering
FY Revenue (est.)
$38.9Bnext fiscal year
FY EPS (est.)
$22.99next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Next Earnings Release | 3 Nov 2026 |
Monitoring Framework
Watch Items
- MariTide Phase 3 program execution and pivotal-study continuityAction: Reassess the probability and timing of MariTide becoming a material long-term growth driver.
- TAVNEOS United States regulatory proceedingAction: Reassess the rare-disease outlook, associated asset value and broader regulatory-execution assumptions.
Research as of 29 Aug 2026